In this video, Kate Cwynarski, FRCP, FCRPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, and Andrew Davies, MRCP, PhD, University of Southampton, Southampton, UK, hold a fascinating discussion highlighting the lymphoma and chronic lymphocytic leukemia (CLL) session held at BSH 2022. Dr Cwynarski and Dr Davies deep dive into clinical trials and novel treatment approaches in lymphoma, and upcoming research in the UK. First, Dr Cwynarski and Dr Davies discuss the POLARIX study (NCT03274492), including the progression-free survival (PFS) and event-free survival (EFS) that was observed in this trial. Following this, Dr Cwynarski and Dr Davies discuss the REMoDL-A trial investigating the addition of acalabrutinib plus standard of care (SOC) R-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Dr Davies and Dr Cwynarski then highlight some other trials, including the PHOENIX trial (NCT01855750) and the FLAIR trial (ISRCTN01844152) and the potential benefit of using acalabrutinib in treatment. Dr Cwynarski and Dr Davies then discuss CNS lymphoma, and the need to continue investigating methods of reducing CNS risk in patients with DLBCL. To conclude, Dr Cwynarski and Dr Davies highlight some clinical trials in primary and secondary CNS lymphoma, including the PRiZM trial (ISRCTN90634455) and the MARIETTA trial (NCT02329080), and the role of novel agents in the future treatment of secondary CNS lymphoma. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, comments on his highlights in the field of lymphoma presented at ASH 2021, including the Phase III POLARIX trial (NCT03274492) of polatuzumab vedotin (R-CHP) in diffuse large B-cell lymphoma (DLBCL). Dr Mehta additionally talks on the ZUMA-7 (NCT03391466), TRANSFORM (NCT03575351), BELINDA (NCT03570892), and ELARA (NCT03568461) trials, which all assessed chimeric antigen receptor (CAR) T-cell therapies, as well as bispecific antibodies such as glofitamab and mosunetuzumab. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the findings from recent studies investigating treatment options for non-Hodgkin lymphoma. Dr Collins focuses on the POLARIX study (NCT03274492), which compares R-CHOP with polatuzumab vedotin plus R-CHP. Results indicate an increased progression-free survival (PFS) and a reduction in subsequent anti-lymphoma treatments. Dr Collins also discusses factors which may influence the future use of this treatment in diffuse large B-cell lymphoma (DLBCL). This interview took place at the 63rd American Society of Hematology Annual Meeting and Exposition, Atlanta, 2021.
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, provides key updates in the field of diffuse large B-cell lymphoma (DLBCL) that will be discussed at ASL 2021. He comments on the results from the Phase III ZUMA-7 trial (NCT03391466) which investigated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory (r/r) DLBCL. Dr Cheah additionally highlights potential data from the Phase III POLARIX trial (NCT03274492), which compared polatuzumab vedotin, an antibody-drug conjugate, with R-CHP against R-CHOP. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives an overview of the main updates in diffuse large B-cell lymphoma (DLBCL) that will be discussed at the upcoming ASH annual meeting. To begin with, the data from the POLARIX trial comparing the efficacy of polatuzumab vedotin plus R-CHP versus R-CHOP in previously untreated DLBCL (NCT03274492) is eagerly awaited, as a recent press release reported that the primary endpoint was met. In addition, updates from the ZUMA-7 study investigating the efficacy of axicabtagene ciloleucel versus standard of care (SOC) in relapsed/refractory DLBCL (NCT03391466) will be presented at ASH, as well as new exciting data on bispecific antibodies for lymphoma. Dr Collins is also looking forward to hearing more details about the real-world data from a study evaluating the outcomes of different central nervous system (CNS) prophylaxis strategies in DLBCL which could have a substantial impact on clinical practice. Finally, an interesting study investigating the use of cell-free DNA (cfDNA) as a diagnostic and prognostic biomarker in primary CNS lymphoma will be presented at the Plenary Scientific Session. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.